Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjogren's syndrome
Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjogren's syndrome
复制标题
白芍总苷对原发性干燥综合征PD-1/PD-L1表达的影响
DOI：
10.1111/1756-185x.13391
复制
发表时间：
2019-02-01
影响因子：
2.5
通讯作者：
Xu, Bo
中科院分区：
文献类型：
--
作者：
Chen, Yueyue;Wang, Yue;Xu, Bo
目的研究白芍总苷(TGP)对原发性干燥综合征(PSS)患者外周血细胞程序性死亡蛋白1(PD-1)及其配体(PD-L1)表达的影响。方法选择10例初发PSS患者为试验组，给予白芍总苷1.8g，每日1次，疗程3个月，并选择10例健康体检者作为对照组。分离外周血单个核细胞，用流式细胞仪检测治疗前后CD4+T、CD8+T细胞表面PD-1的表达及CD14+单核细胞、CD19+B细胞表面PD-L1的表达。采用酶联免疫吸附试验检测血浆中可溶性PD-1、IL-10和IL-17A的水平。结果pSS患者外周血中CD_4~+T、CD_8~+T细胞表面PD-1的表达明显高于对照组(P<0.001)。CD14+单核细胞表面PD-L1表达下降但不明显(P>；0.001)，CD19+B细胞表面PD-L1表达显著增加(P<；0.05)。此外，实验组血浆Spd-1、IL-17A水平显著高于对照组(P<0.001)，而IL-10水平显著低于对照组(P<；0.001)。治疗后，pSS患者外周血中CD_4~+T、CD_8~+淋巴细胞表面PD-1的表达显著降低(P<0.001)，CD_(19+)细胞表面PD-L1的表达显著降低(P<0.001)，CD_(14+)单核细胞表面PD-L1的表达无明显差异(P>；0.05)。治疗后血浆Spd-1、IL-17A水平下降(P<0.01)，IL-10水平升高(P<；0.01)。结论表达于T细胞、B细胞和单核细胞表面的PD-1/PD-L1分子通过相互作用参与SS的发生发展。因此，TGP可能通过调节调节性T细胞/辅助性T细胞17，通过PD-1/PD-L1途径在SS的发生发展中发挥作用，可能通过上调PD-1及其相关配体PD-L1在SS的发生发展中发挥作用。
Aim To study the influence of total glucosides of paeony (TGP) on the expression of peripheral blood programmed cell death protein 1 (PD-1) and its ligand (PD-L1) in patients with primary Sjogren's syndrome (pSS). Method Ten patients with new-onset pSS were selected as the experimental group and were treated with 1.8 g of TGP (the main ingredient is Radix Paeoniae Alba) daily for 3 months; furthermore, 10 physically healthy individuals were selected as the control group. Peripheral blood mononuclear cells were isolated, and flow cytometry was used to detect PD-1 expression on the surface of CD4+ T and CD8+ T lymphocytes and PD-L1 expression on the surface of CD14+ monocytes and CD19+ B cells before and after treatment in the experimental and control groups. Furthermore, plasma levels of soluble PD-1 (sPD-1), interleukin (IL)-10, and IL-17A were also determined using enzyme-linked immunosorbent assay. Results The PD-1 expression on the surface of CD4+ T and CD8+ T lymphocytes in the peripheral blood of patients with pSS were significantly higher than in the control group (P < 0.001). However, PD-L1 expression on the surface of CD14+ monocytes declined but not significantly (P > 0.05), and PD-L1 expression on the surface of CD19+ B cells increased significantly (P < 0.001). Moreover, sPD-1 and IL-17A levels in the plasma of the experimental group were significantly higher than in the control group (P < 0.001), but the IL-10 level was significantly lower than in the control group (P < 0.001). After TGP treatment, PD-1 expression on the surface of CD4+ T and CD8+ lymphocytes in the peripheral blood of patients with pSS had decreased significantly (P < 0.001); the PD-L1 expression on the surface of CD19+ cells had decreased significantly (P < 0.001); and the PD-L1 expression on the surface of CD14+ monocytes did not differ significantly (P > 0.05). Furthermore, the levels of sPD-1 and IL-17A in plasma had decreased (P < 0.01) and IL-10 levels had increased after TGP treatment (P < 0.01). Conclusion PD-1/PD-L1 molecules expressed on the surface of T cells, B cells, and monokaryon participated in the pathogenesis and development of SS through interactions. Therefore, TGP, which may increase the expression of PD-1 and its relevant ligand PD-L1 in the peripheral blood mononuclear cells, may play a role in the pathogenesis and development of SS through the PD-1/PD-L1 pathway by regulating regulatory T cells/T helper cell 17.